Ekf Diagnostics Share Discussion Threads

[rivaldo] 10/11/2020 14:22

Nice bounce. Sanity being restored :o))

[tongosti] 10/11/2020 12:48

Time to hear the cash register ring again. Covered my final third for another +5% and change. +48% trading both sides over the last few weeks. Gracias Senor Mercado

[wan] 10/11/2020 10:39

I note that Chris Mills, across his various vehicles, has increased the holding in Source Bio to over 29% (inline with his holding in EKF) -

10 November 2020|RNS

[tongosti] 10/11/2020 10:32

Ok pal - live and let's live as that's what makes a market. I just see volumes skyrocketing today as well on the way down. I am personally happy to ride my short to whatever it takes me so that aside I genuinely wish you luck.

[wan] 10/11/2020 10:17

I now take it back about other diagnostic stocks recovering!

But I stick with my view that EKF is differentiated in its diagnostics offering, coronavirus or otherwise, including post any successful development/authorisation of vaccines and the resulting requirement for antibody tests, and indeed the continued requirement and wide use of coronavirus testing.

[tongosti] 10/11/2020 09:47

I see your point of view but do not necessarily agree with your assessment post Pfizer vaccine. It's a long story but suffice to say that market's action confirms how I think about related implications (I made this point immediately after the vaccine news broke out yesterday). In broader terms, to me the ultimate fundamental is the market action and I never play macho with it. Doesn't matter how you cut it, we never make money on our opinions but by being in sync with the market action. Always and without fail (opinions pay off if and only if they positively correlate with market action).

[wan] 10/11/2020 09:39

I agree that markets overreact in either direction. However, it's not as if EKF are over reliant on testing alone, or even the development of a test like some companies are. EKF has significant cash in the bank and generates real positive cash flow.

The vaccine news does not change the fact that EKF's full year performance has further exceeded market consensus and will result in record revenues for the year. And the dramatic expansion of testing suggests there could be more in the tank yet.

Also, vaccines will add requirements for antibody testing, especially those that complete phase 3 like Pfizer and BioNTech (nb: BioNTech is German). The Kantaro/EKF 'quantitative antibody test is backed up by diverse data and real clinical usage, and I can confirm that that is a major differentiating feature compared to some single use 'qualitative' tests on the market/in development, some of which apparently don't even work!

[tongosti] 10/11/2020 09:08

What you are missing is understanding Mr Market. Honestly, this is not tongue in cheek but a genuine comment. There is a two way feedback loop between market action and fundamentals not a one way street like most believe. George Soros calls it Reflexivity. I would go read I'm about it if I were you. Cheers.

[wan] 10/11/2020 08:57

What am I missing, other diagnostic stocks are recovering?

EKF's core business is recovering and testing volumes are expanding!

[tongosti] 10/11/2020 08:56

Not really mate - it is the investor community who had already reacted way prior to the release. I made the point a few days ago that price action proceeds fundamentals. That is what is in play. For the avoidance of doubt - I am not having a go at anyone. Just a (very) different point of view. That's what makes a market I hear you say.

[wanttowin] 10/11/2020 08:46

Crazy market reaction to an ahead of expectations update !

[tongosti] 10/11/2020 08:44

Momentum proceeding price. Like I said yesterday 54 is the next immediate target with 45 past that. Still have a third of my original position on trying to surf the wave South. PS. MG - thanks for your post. As you can see I am giving my opinion on what I see in the market. I am done with those who were at my throats simply because of a difference in opinion.

[mg1982] 10/11/2020 07:54

tongosti,

Can you please give it a rest now. You've made your point, you are a trader. We get it.

That is fine, no problem. Some of us have been in EKF for a while now and understand the core business and how CV19 has and is affecting them. Our timeframes are longer.

We are playing a different strategy to yours.

Both can make money if they play it right

[tongosti] 10/11/2020 07:45

So your hope is that investors have over-reacted?Hope is the most expensive word in the money-making business pal.

[wan] 10/11/2020 07:15

Most analysts believe that investors may have overreacted -

Promising Coronavirus Vaccine News Leads to Share-Price Slide for Bevy of Dx Companies
Nov 09, 2020 | staff reporter

"In terms of implications for diagnostics companies, sooner vaccine availability obviously translates into a shorter duration of testing tailwinds, and we continue to see downside risk for companies that are over-levered to COVID-19 testing," such as GenMark, Luminex, OraSure Technologies, and Quidel, Tycho Peterson, an analyst at JP Morgan, said in a research note.

Other analysts believe that investors may have overreacted. Brian Weinstein, an analyst at William Blair, said in a research note on Monday that "there is likely to be an overreaction to the downside on these stocks today as investors take the news as being an instant panacea and one that eliminates the need for any COVID-19 testing."

Although the prospect of a vaccine is "unequivocally positive … we still believe there is a lot of testing that will need to be done in the future," he added.

Piper Sandler analyst Steven Mah said in a research note that he believes the sell-off is an overreaction and "presents a buying opportunity for highly differentiated testing companies," such as Quidel, Fulgent Genetics, Fluidigm, Luminex, and Meridian Bioscience.

Mah said that the investment bank expects that large-scale population testing, contact tracing, and effective quarantining policies will accelerate and "be needed for the next few years to safely return to normal even with a highly effective vaccine."

He noted that many of the companies he listed "already have long-term COVID-19 testing contracts which underscore the utility of COVID-19 testing to healthcare providers."

Peterson said that for diversified companies such as Hologic, whose share price was down almost 9 percent to $68.35 at the close of the market on Monday, "positive vaccine updates should bode well for the base business recovery … offsetting a potential impact on testing tailwinds."

Fulgent Genetics Chairman and CEO Ming Hsieh said during a conference call to discuss the company's Q3 financial results on Monday that he welcomes the news associated with the development of a vaccine. Vaccines are adding additional requirements for antibody testing, he said, "creating a new opportunity for Fulgent Genetics in this space. I do not believe that COVID-19 will go away easily."

Full story -

[wan] 10/11/2020 07:11

Testing is not going to reduce anytime soon.........in fact it is being dramatically expanded and accelerated!

At the PM's Briefing yesterday, it was confirmed that the mass testing at Liverpool will be significantly expanded, with many more testing sites opening in the next few weeks. But there is more, a lot more -

Exclusive: Mass testing to be rolled out at universities to get students home for Christmas

The Telegraph can reveal that the Government’s strategy involves setting up large scale asymptomatic testing programmes at universities

9 November 2020 • 9:00pm
Mass testing is to be rolled out at universities to get students home safely for Christmas, under plans due to be announced this week.

The Prime Minister said on Monday that official guidance will shortly be issued on how universities should manage the mass movement of students at the end of term in a way that does not risk spreading the virus around the country.

The Telegraph can reveal that the Government’s strategy involves setting up large scale asymptomatic testing programmes at universities so that students with a negative test result can safely travel home.

“The letter has gone out to every university head and my understanding is the vast majority are saying yes they do want to take part,” a source said. “They see it as a good way of getting their students home safely for Christmas.”
Full story -

[lastoneout] 10/11/2020 00:14

Just watching Sky and the Pfizer vac is BNT162b2. The full spike protein.

[btgman] 09/11/2020 22:35

Apologies if this has already been posted




GLA
BTG

[tongosti] 09/11/2020 19:33

Post of the day from yours truly fellas. Homework, homework, homework...

09:06 Odds for a meaningful (at least) major consolidation (or worse!) around existing levels have risen to 93% including last Friday's data.

[hastings] 09/11/2020 17:59

"You're ready now"!!

[andrewbaker] 09/11/2020 17:54

The company's involvement with covid-19 testing, precautions, et al, mean, for me, that the drop is a buying opportunity. I'm already heavy on EKF, so don't know whether to buy more for risk of going top-heavy; but I'm holding on to what I've got (as Frankie Valli tells us, lol). And yes, I was around when he first sang it, and I still know the words. :)

[wan] 09/11/2020 17:38

With the reality setting in that testing will not be reducing anytime soon, today's pullback may look well overdone by tomorrow morning! Time will tell.

[wan] 09/11/2020 17:19

The vaccines breakthrough is good news as some of us indeed acknowledged, but it's still early days, with testing, testing, testing, still a very important part of the fight against Covid-19, and acknowledged as 'remaining' very important both here in the UK and in the US!

Lateral Flow antigen tests actually featured on the PM's briefing.